French health tech startup Remedee Labs, designer of the first endorphin stimulator for personal use, is hiring Gilles Litman to accelerate growth. As Chief Business Officer, Gilles will be responsible for launching Remedee Digital Service Platform, the breakthrough technology platform actively changing the lives of patients with chronic pain, in addition to accelerating the company’s international expansion.
Before joining Remedee Labs, Gilles was the VP of Digital Health at Sanofi, where he worked on technology platforms focused on diabetes and cardiovascular diseases. A graduate of ESSEC Paris, Gilles has over 20 years’ experience in the pharmaceutical industry, with a distinguished expertise in strategy, international development, and business management.
Changing the lives of chronic pain patients through an endorphin stimulator and a digital service platform
Remedee Labs has developed a groundbreaking, first-of-its-kind, non-invasive endorphin stimulation technology to improve quality of life for patients with chronic pain.
Remedee Platform allows a comprehensive and personalized experience through multidisciplinary care designed for both patients and practitioners. The Platform enables remote support by care teams, coaches, practitioners and more, and includes personalized digital services available 24/7.
Useful for conditions with no satisfactory treatment such as fibromyalgia and endometriosis, but also migraines and osteoarthritis
Fibromyalgia is a debilitating chronic condition that affects many aspects of healthy living and quality of life. Treatment options are inconsistently effective, can be expensive, and often come with host of unwelcome side effects.
Technology developed by Remedee Labs to reduce stress and improve sleep has been shown to significantly improve the quality of life of patients suffering from fibromyalgia. In light of these promising results, Remedee Labs is launching a multi-center study on fibromyalgia and developing the first personalized support pathway for this condition.
Global development potential
Endorphin stimulation using millimeter waves as an alternative for chronic pain management
Remedee Labs has designed and developed the first endorphin stimulation solution, which is transforming chronic pain management.
The result of many years of scientific research and strong partnerships (CEA-Leti, ST Microelectronics), this technology is based on the patented MEET (Microelectronic Endorphin Trigger) module, the first miniature module that emits millimeter waves. Embedded in a bracelet and placed on the inside of the wrist, this module delivers an ultra-high frequency electronic signal that accurately stimulates the subcutaneous receptors (0.5 mm inside the skin).
In response to this painless nerve stimulation, the brain releases intracerebral endorphins that rapidly ease the pain and also produce a feeling of well-being.
About Remedee Labs
1.5 billion people worldwide suffer from chronic pain and over half of them are not satisfied with their care. Remedee Labs aims to give these patients a new life.
Based on 10 years of pre-clinical and clinical research, Remedee Labs has developed the first endorphin stimulator for personal use. Building on the experience of its clinical partners, the company now uses its unique technology to offer the first patient-centered digital service platform for chronic pain management, working alongside medical practitioners. Remedee Labs initial focus is helping patients with fibromyalgia, and plans extend the Platform offering to other chronic pain conditions in the coming future.
Founded in 2016, Remedee Labs announced in 2019 that it had raised 11 million euros from investors, including HCVC, Habert Dassault Finance, Partech, Supernova Invest and C4 Venture.
